Clinical

FDA approval announces the first biosimilar in the USA for ranibizumab (Lucentis) intravitreal injection in neovascular AMD, RVO and myopic CNV

The US FDA (Food and Drug Administration) has approved authorisation for “Byooviz” (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) “for the treatment of… Read More »FDA approval announces the first biosimilar in the USA for ranibizumab (Lucentis) intravitreal injection in neovascular AMD, RVO and myopic CNV

A systematic review and meta-analysis on individual participant data, within 5 RCTs, on the treatment of ocriplasmin for vitreomacular adhesion resolution.

Researchers from King’s College London, UK have published a systematic review and meta-analysis on individual participant data from RCT literature using evidence on ocriplasmin’s effect… Read More »A systematic review and meta-analysis on individual participant data, within 5 RCTs, on the treatment of ocriplasmin for vitreomacular adhesion resolution.

A clinical study on eye colour, using genome-wide association analysis, has identified 50 previously unidentified genetic loci

Researchers at King’s College London, UK have reported that 192,986 European participants, across 10 populations, have identified 124 independent associations arising from 61 discrete genomic… Read More »A clinical study on eye colour, using genome-wide association analysis, has identified 50 previously unidentified genetic loci